Business

Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma into the Priority Review Program

Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma into the Priority Review Program

articleSichuan Biokin Pharmaceutical Co., Ltd. Class ASeptember 5, 20254/news/announcement-on-voluntary-disclosure-of-inclusion-of-iza-bren-egfrher3-bispecific-adc-for-the-treatment-of-locally-advanced-or-metastatic-nasopharyngeal-carcinoma-into-the-priority-review-program
Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma into the Priority Review Program

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma into the Priority Review ProgramThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A